Authorised psychiatrists are now able to prescribe MDMA and psilocybin for PTSD and treatment-resistant depression, respectively, from 1 July.
The high of MDMA (a.k.a.
For the first time, the U.S.
Psychedelics stand at a pivotal crossroads in mental health, offering the prospect of novel therapeutic avenues to address multiple mental conditions, from treatment-resistant depression to post-traumatic...
The UK’s Medicines and Healthcare Products Regulatory Authority (MHRA) has approved a trial investigating psilocin for major depressive disorder (MDD) that will be carried out in...
PSYCH Symposium is returning at the British Museum on 6 July, when a panel of changemakers and MEPs will discuss the future of psychedelic healthcare in...
Alexander Shulgin, best known for introducing MDMA to the psychological community, also created over 230 novel psychoactive compounds and documented their effects in the book PiHKAL:...
New findings from an animal study show that psychedelics open a ‘critical period’ of social reward learning in the brain, but that different psychedelics do so...
Brazilian indigenous spiritual leader, Chief iIxiwaka Biraci Yawanawa, will be giving a keynote address on June 23 on the ‘Importance of Protecting Ayahuasca Biocultures From Commercialization,...
COMPASS Pathways and MAPS Public Benefit Corporation (PBC) have put forward a joint application for a new code to facilitate access to psychedelic therapies in the...